Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 12:36:37 2025-03-19 EDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+0.11%-1.89%+16.22%-11.26% 66.25B
-0.12%+3.10%+40.83%+196.27% 52.86B
+0.51%+37.90%+37.90%+37.90% 43.01B
-1.86%-4.93%-56.15%-56.66% 39.52B
+1.46%+1.71%+56.92%-27.51% 29.19B
+0.78%+1.39%+69.36%+81.90% 23.13B
-1.81%-16.49%+74.21%-54.90% 23.04B
-1.30%-6.18%+3.94%+177.59% 20.48B
-1.04%+0.53%+69.40%+119.96% 16.6B
Average -0.21%-2.11%+22.37%+36.41% 34.9B
Weighted average by Cap. -0.14%-1.59%+28.18%+46.09%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B